Matches in Nanopublications for { ?s ?p "[Despite increasing use of targeted therapy, interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP894726.RAoVZWH9KHgzFk-xmi9CrM-m8Sb8uODmBzWTS0cGz4MKM130_assertion description "[Despite increasing use of targeted therapy, interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894726.RAoVZWH9KHgzFk-xmi9CrM-m8Sb8uODmBzWTS0cGz4MKM130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion description "[Despite increasing use of targeted therapy, interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894728.RAJfJmXWnZo7b60UCLaNBF2s6rQiMlztPY5tb8JEPpoiU130_assertion description "[Despite increasing use of targeted therapy, interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894728.RAJfJmXWnZo7b60UCLaNBF2s6rQiMlztPY5tb8JEPpoiU130_provenance.